StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
06/13/2025 16:10:00 EST
GlaxoSmithKline PLC ADR (GSK)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, GSK has been trading in a range between $41.66 and $37.64 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
GSK is trading below resistance at $41.66, about 2% to the upside. There is support at $38.40 -6% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
GlaxoSmithKline PLC ADR $GSK entered a Green zone 19 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $41.5357, a potential upside of 1.65% from the recent price of 40.86. The stock is trading 5.7% (potential upside) below its 52 week high of $43.19 and 31.76 % (potential downside) above its 52 week low of $31.01 - based on the recent price.
Company Summary
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
News
| GSK seeks broader European approval for RSV vaccine GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with the European Medicines Agency accepting its application to expand the vaccine's use to all adults aged 18 and over. The vaccine, sold under the name Arexvy, is already authorised across Europe for adults aged 60 and over, as well as those aged 50 to 59 who are at increased risk due to underlying health conditions. Source: Proactive Investors Fri, 13 Jun 2025 05:01:25 -0400 Sentiment: Positive |
| GSK says EU heath regulator reviewing expansion of RSV vaccine GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age. Source: Reuters Fri, 13 Jun 2025 02:14:33 -0400 Sentiment: Positive |
| Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions. Source: Investors Business Daily Mon, 09 Jun 2025 18:07:53 -0400 Sentiment: Negative |
| Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Source: Benzinga Mon, 09 Jun 2025 09:19:57 -0400 Sentiment: Positive |
| Here's Why GSK (GSK) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Source: Zacks Investment Research Fri, 06 Jun 2025 10:41:08 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 43.1867 52 Week Low: 31.0127 Beta: 0.274 50 Day MA: 38.1184 200 Day MA: 37.5294 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.547 Qtr Revenue Growth YOY: 0.021 Forward PE: 9.1743 Trailing PE: 19.835